Search - tctmd.com

Displaying 21 - 40 of 59

Sort: Relevancy | Date

News Daily News

Papers Probe Temporal Link Between COVID-19 Vaccines and Myocarditis

Michael O'Riordan

June 17, 2021

News Daily News

Xience Cleared in Europe for 1-Month DAPT in High-Bleeding-Risk Patients

Shelley Wood

April 06, 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for March 2021

Shelley Wood

April 02, 2021

News Daily News

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Michael O'Riordan

March 03, 2021

News Daily News

New FDA Indication Opens Up Use of Sacubitril/Valsartan in HFpEF

Todd Neale

February 16, 2021

News Daily News

FDA Approves Evinacumab for Rare Homozygous FH

Michael O'Riordan

February 11, 2021

News Daily News

FDA Approves Vericiguat for High-risk Patients With HF

Michael O'Riordan

January 20, 2021

News Daily News

Inclisiran Approved in Europe for Lowering LDL Cholesterol

Michael O'Riordan

December 11, 2020

News Conference News EAS 2020

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

Michael O'Riordan

October 08, 2020

News Daily News

FDA Extends Ticagrelor Indication to High-Risk CAD Primary Prevention

Shelley Wood

June 01, 2020

News Conference News STS 2020

TAVR Tussle at US Surgery Meeting Threatens to Widen Surgeon-Cardiologist Wedge

Yael L. Maxwell

January 29, 2020

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

News Daily News

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Michael O'Riordan

January 03, 2020

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

News Daily News

Sapien 3 Valve Approved in Europe for Low-Risk Patients

Michael O'Riordan

November 06, 2019

News Daily News

FDA Gives Rivaroxaban Another VTE-Related Indication

Todd Neale

October 14, 2019

News Daily News

FDA Expands TAVR Indication to Low-Risk Patients

Michael O'Riordan

August 16, 2019

News Daily News

FDA Approves Dalteparin Sodium as First Anticoagulant For Use in Pediatric VTE Patients

Yael L. Maxwell

May 16, 2019

News Daily News

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Michael O'Riordan

April 29, 2019

News Daily News

FDA Approves Pea-Sized Occluder for Patent Ductus Arteriosus in Premature Babies

L.A. McKeown

January 14, 2019

Advertisement

Papers Probe Temporal Link Between COVID-19 Vaccines and Myocarditis

Xience Cleared in Europe for 1-Month DAPT in High-Bleeding-Risk Patients

TCTMD’s Top 10 Most Popular Stories for March 2021

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

New FDA Indication Opens Up Use of Sacubitril/Valsartan in HFpEF

FDA Approves Evinacumab for Rare Homozygous FH

FDA Approves Vericiguat for High-risk Patients With HF

Inclisiran Approved in Europe for Lowering LDL Cholesterol

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

FDA Extends Ticagrelor Indication to High-Risk CAD Primary Prevention

TAVR Tussle at US Surgery Meeting Threatens to Widen Surgeon-Cardiologist Wedge

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Sapien 3 Valve Approved in Europe for Low-Risk Patients

FDA Gives Rivaroxaban Another VTE-Related Indication

FDA Expands TAVR Indication to Low-Risk Patients

FDA Approves Dalteparin Sodium as First Anticoagulant For Use in Pediatric VTE Patients

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

FDA Approves Pea-Sized Occluder for Patent Ductus Arteriosus in Premature Babies

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content